Fortrea Holdings Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Fortrea, a global contract research organization serving pharmaceutical, biotechnology and medical-device customers, was spun off from Labcorp on June 30 and began trading independently on July 3. Prior-period results are carve-out financials and may not reflect standalone costs; the June 30 balance sheet is for Fortrea as a standalone company.
Financial performance
| Metric ($ millions, except per-share data) | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | 793.0 | 793.1 | 1,557.2 | 1,572.1 |
| Operating income | 33.8 | 71.2 | 59.8 | 103.9 |
| Net income | 28.3 | 66.4 | 45.7 | 98.9 |
| Diluted EPS | $0.32 | $0.75 | $0.51 | $1.11 |
| Operating margin | 4.3% | 9.0% | 3.8% | 6.6% |
Q2 revenue was essentially flat; first-half revenue declined 0.9%, including a 0.2% organic decline and 0.7% unfavorable foreign-currency impact. Q2 direct costs rose 5.7% to $649.4, increasing to 81.9% of revenue from 77.5%; SG&A rose 13.5% to $80.8. Management attributed higher direct costs primarily to pass-through costs, which are generally offset by corresponding revenue, and lower service revenue to a prior-year FSP cancellation, a customer concession, and the mix and quantity of recent wins. SG&A increases included indirect labor, credit-loss provisions and $5.4 of additional one-time Former Parent costs. Net income also reflected lower foreign-exchange gains and higher effective tax rates.
Clinical Services generated Q2 revenue of $726.1, up 0.4%, but segment operating income fell 36.1% to $74.1. Enabling Services revenue declined 4.2% to $66.9 and segment operating income fell 89.0% to $1.2, reflecting cancellations and investment to serve a recent award. First-half segment operating income declined 34.2% to $136.2. Restructuring charges were $3.9 in Q2 and $5.1 for the half, below the prior-year $13.0 and $22.6, respectively.
Cash flow, liquidity and debt
- First-half operating cash flow was $154.2, versus cash used of $21.7 in 2022; management cited improved collections and working-capital movements, partly offset by lower net income.
- Capital expenditures were $25.8, compared with $19.0 a year earlier. Cash and equivalents were $114.3 at June 30, versus $112.0 at year-end 2022.
- Fortrea incurred approximately $1.64 billion of debt in connection with the separation: $570 million of 7.5% senior notes due 2030, plus term loans. The balance sheet reported $1,578.9 million of long-term debt, net of discounts and fees, and $26.1 million of short-term borrowings/current debt.
- The $1.07 billion of term loans outstanding included variable-rate debt; effective rates at June 30 were 7.49% on Term A and 8.99% on Term B. A 1-percentage-point rate increase would add an estimated $10.7 million of annual interest expense before hedging. A $450 million revolving facility was undrawn at quarter-end.
- The company paid Labcorp $1.595 billion in connection with the separation. It also established an accounts-receivable purchase facility of up to $80 million and sold $17.5 million of receivables for $17.3 million in proceeds.
Management stated that cash, operating cash flows and available financing were expected to cover current and planned operating needs for at least the next 12 months. The company was in compliance with its credit-facility covenants at June 30.
Outlook, risks and notable items
- No specific revenue or earnings guidance was provided. Unfulfilled performance obligations on long-term contracts were $4.33 billion; Fortrea expected to recognize approximately 30% as revenue over the next 12 months, with the remainder thereafter. Backlog is not a guarantee of future revenue.
- Management cited risks from the transition to standalone operations and reliance on Labcorp transition services, customer cancellations or delayed awards, contract pricing and cost overruns, macroeconomic conditions, foreign-currency movements and variable-rate debt.
- Goodwill was $2.03 billion. Management warned that adverse assumptions—including weaker revenue growth or margins—could reduce reporting-unit fair values and lead to impairment.
- Legal claims arise in the ordinary course of business; management did not expect related liabilities to materially affect financial condition, results or cash flows. The industry is extensively regulated, and the filing notes potential regulatory and litigation sanctions.
- First-half results include carve-out allocations and tax calculations that may differ from standalone experience. Fortrea also disclosed a $72.1 million unamortized stock-award expense balance associated with awards converted to Fortrea restricted stock units after quarter-end.
Important facts for investors to verify
- Whether service-revenue trends, customer cancellations and new-business awards improve, and whether the $4.33 billion performance-obligation balance converts to revenue as expected.
- How standalone operating expenses compare with historical Labcorp allocations and whether transition-service arrangements create additional costs or execution risks.
- Debt terms, covenant headroom, interest-rate exposure and the company’s ability to sustain cash generation after the separation-related payment.
- Drivers of increased credit-loss provisions and the collectability of receivables, including use of the factoring facility.
- Whether restructuring, foreign exchange, tax and stock-compensation effects materially affect future reported margins and earnings.